PERTH, Australia – Australian biotech Propanc Biopharma Inc. is advancing its lead product, PRP, toward the clinic in ovarian and pancreatic cancers. The Melbourne-based company reported that recent studies show that the once-daily intravenous combo of pancreatic proenzymes trypsinogen and chymotrypsinogen reduced epithelial to mesenchymal transition (EMT) markers, which not only reverses the EMT process, thereby stopping tumor progression and metastasis, but also represses the development of cancer stem cells.